Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial

In this study, efficacy and safety of interferon (IFN) β-1b in the treatment of patients with severe COVID-19 were evaluated. Among an open-label, randomized clinical trial, adult patients (≥18 years old) with severe COVID-19 were randomly assigned (1:1) to the IFN group or the control group. Patien...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int Immunopharmacol
Hlavní autoři: Rahmani, Hamid, Davoudi-Monfared, Effat, Nourian, Anahid, Khalili, Hossein, Hajizadeh, Nooshin, Jalalabadi, Narjes Zarei, Fazeli, Mohammad Reza, Ghazaeian, Monireh, Yekaninejad, Mir Saeed
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier B.V. 2020
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7445008/
https://ncbi.nlm.nih.gov/pubmed/32862111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2020.106903
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky